Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2017-09-27 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for ImmuPharma PLC for the six months ended 30 June 2017. It contains comprehensive financial data, including net assets, loss for the period, research and development expenses, and loss per share, alongside a detailed management discussion (Chairman's Statement) and operational updates. Since it provides substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2017
2017-09-27 English
Preparation of Lupuzor'sT Regulatory Submissions
Legal Proceedings Report Classification · 1% confidence The document is identified by the RNS Number (7616R) and the header 'RNS : FOR IMMEDIATE RELEASE', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses the initiation of preparation for regulatory submissions (FDA and EMA) for the drug Lupuzor™, which is an operational update related to drug development and regulatory compliance. Since it is a general regulatory announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), and it is not a full report itself, the most appropriate classification is the general regulatory filing category, RNS. The document length (5959 chars) is substantial enough that it is not merely an announcement *about* a report being published (RPA), but the substance of the announcement itself.
2017-09-26 English
Update on LupuzorT Pivotal Phase III Study
Legal Proceedings Report Classification · 1% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content provides an update on a clinical trial ('Update on Lupuzor™ Pivotal Phase III Study') and includes key operational and safety data points, but it is not a full financial report (like 10-K or IR) or a formal earnings release (ER). It is a general, timely announcement of corporate/operational progress released via the Regulatory News Service (RNS). Since 'Regulatory Filings' (RNS) is the designated fallback for miscellaneous regulatory announcements that don't fit specific categories like DIRS, DIV, or CAP, this is the most appropriate classification.
2017-09-21 English
Notification of Interim Results
Report Publication Announcement Classification · 1% confidence The document is very short (1274 characters) and explicitly states its purpose in the title: "NOTIFICATION OF INTERIM RESULTS". It announces *when* the Interim results for the six months ended 30 June 2017 will be released (Date: 27 September 2017). This fits the definition of a Report Publication Announcement (RPA), which signals the upcoming release of a report, rather than being the comprehensive report itself (which would likely be classified as IR). The presence of the RNS Number and the 'END' marker further confirms it is a regulatory announcement about a future report release.
2017-09-19 English
AIM Rule 17 Notice
Director's Dealing Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and the explicit mention of 'RNS Number : 4650O' and 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details an 'AIM Rule 17 Notice' regarding a director's disclosure (Tim McCarthy's past board roles). This type of announcement, which reports specific, non-standard corporate actions or disclosures required by the exchange (AIM Rules), fits best under the general 'Regulatory Filings' category (RNS) as it is not a standard financial report (10-K, IR, ER) or a specific insider trade report (DIRS), although it relates to a director. Given the structure and source (RNS), RNS is the most appropriate classification, as it serves as the general regulatory announcement fallback.
2017-08-18 English
Grant of Options
Remuneration Information Classification · 1% confidence The document is a formal announcement dated July 12, 2017, issued via 'RNS Number : 8456K' from Immupharma PLC. The content details the 'Grant of Options' over ordinary shares to non-executive Directors, including specific numbers, exercise prices, and vesting schedules. This type of filing, which reports personal share transactions or option grants by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions 'inside information' and is distributed via RNS, the specific subject matter (Director option grants) makes DIRS the most precise classification over the general RNS fallback.
2017-07-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.